Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T Predict Outcome of Platinum-based Chemotherapies in Advanced Non-small Cell Lung Cancer: A Meta-analysis

Archives of Medical Research

Volumn 42, Issue 5, 2011, Pages 412-420

  Wei, Hai bo ^a   Lu, Xiang shi ^a   Shang, Li hua ^a   Xu, Gang ^a   Hu, Jing ^a   Che, De hai ^a   Liu, Fang ^a   Wu, Ying ^a   Zhang, Guang mei ^a   Yu, Yan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; ERCC1; MDR1; Meta analysis; Non small cell lung; Platinum

Indexed keywords

CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; PLATINUM;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; PREDICTIVE VALUE; PROTEIN POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; ENDONUCLEASES; HUMANS; LUNG NEOPLASMS; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 80052755181     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.07.008     Document Type: Article

References (47)

1. Voicu-Maceseanu A., Nitu M., Olteanu M., et al. Epidemiology of lung cancer. Pneumologia 2007, 56:78-84.
2. Spiro S.G., Silvestri G.A. The treatment of advanced non-small cell lung cancer. Curr Opin Pulm Med 2005, 11:287-291.
3. Rosell R., Cecere F., Santarpia M., et al. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol 2006, 6:323-331.
4. Simon G.R., Sharma S., Cantor A., et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005, 127:978-983.
5. Rosell R., Taron M., Ariza A., et al. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 2004, 31:20-27.
6. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
7. Furuta T., Ueda T., Aune G., et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002, 62:4899-4902.
8. Ma H., Xu L., Yuan J., et al. Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1 (ERCC1) and risk of primary lung cancer in a Chinese population. Pharmacogenet Genomics 2007, 17:417-423.
9. Yu J.J., Lee K.B., Mu C., et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000, 16:555-560.
10. Zhang L., Liu T., Zhang J.Q. Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2011, 33:212-216.
11. Terek M.C., Zekioglu O., Sendag F., et al. MDR1 gene expression in endometrial carcinoma. Int J Gynecol Cancer 2003, 13:637-677.
12. Leonessa F., Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003, 10:43-73.
13. Sauna Z.E., Smith M.M., Muller M., et al. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 2001, 33:481-491.
14. Sakaeda T., Nakamura T., Okumura K. MDR1 genetype-related pharmaco-kinetics and pharmacodynamics. Biol Pharm Bull 2002, 25:1391-1400.
15. Takara K., Sakaeda T., Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 2006, 12:273-286.
16. Brinkmann U., Eichelbaum M. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J 2001, 1:59-64.
17. Hoffmeyer S., Burk O., von Richter O., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000, 97:3473-3478.
18. Ito S., Ieiri I., Tanabe M., et al. Polymorphism of the ABC transportergenes. MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001, 11:175-184.
19. Pan J.H., Han J.X., Wu J.M., et al. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 2008, 75:380-385.
20. Tierney J.F., Stewart L.A., Ghersi D., et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
21. Lin D.Y., Sullivan P.F. Meta-analysis of genome-wide association studies with overlapping subjects. Am J Hum Genet 2009, 85:862-872.
22. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration 2009.
23. De las Penas R., Sanchez-Ronco M., Alberola V., et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006, 17:668-675.
24. Gandara D.R., Kawaguchi T., Crowley J., et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009, 27:3540-3546.
25. Ryu J.S., Hong Y.C., Han H.S., et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004, 44:311-316.
26. Isla D., Sarries C., Rosell R., et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004, 15:1194-1203.
27. Zhou W., Gurubhagavatula S., Liu G., et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004, 10:4939-4943. Available at:. http://www.ncbi.nlm.nih.gov/pubmed?term%3D%2522Park%2520S%2522%255BAuthor%255D.
28. Su D., Ma S., Liu P., et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007, 56:281-288.
29. Park S.Y., Hong Y.C., Kim J.H., et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med Oncol 2006, 23:489-498.
30. Tibaldi C., Giovannetti E., Vasile E., et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008, 14:1797-1803.
31. Kalikaki A., Kanaki M., Vassalou H., et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009, 10:118-123.
32. Gao C.M., Shi M.Q., Wu J.Z., et al. Polymorphisms in ERCC1, XRCC1 genes and sensitivity to gemcitabine/cisplatin chemotherapy in non-small cell lung cancer. Chin J Cancer Prev Treat 2010, 16:27-30.
33. Ren BH, Yang X, Li M, et al. Single nucleotide polymorphisms in DNA repair gene ERCCl predict clinical response to platinum based chemotherapy in non-small cell lung cancer 2010;27:1200-1202.
34. Chen S., Huo X., Lin Y., et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health 2010, 213:140-145.
35. Su T., Zhao L.J., Chang W.J., et al. Relationship of ERCC1, XPD, and BRCA1 polymorphisms with efficacy of platinum-based chemotherapy for patients with advanced non-small cell lung cancer. Acad J Second Military Med Univ (Chin) 2010, 31:117-122.
36. Wang J.H., Zhang Q., Zhang H., et al. Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy. Chin J Lung Cancer 2010, 13:337-341.
37. Li X.H., Jiang W.F., Zhang H.L., et al. Relationship between SNPs of ERCC1 in peripheral blood of NSCLC and effects of cisplatin-based chemotherapy. Chin J Cancer Prev Treat 2010, 17:169-172.
38. Zhou C., Ren S., Zhou S., et al. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol 2010, 40:954-960.
39. Li F., Sun X., Sun N., et al. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol 2010, 33:489-494.
40. Vinolas N., Provencio M., Reguart N., et al. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 2011, 71:191-198.
41. KimCurran V., Zhou C., Schmid-Bindert G., et al. Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer. Adv Med Sci 2011, 56:1-9.
42. Yu Q.Z., Han J.X., Pan J.H., et al. The relationship between the polymorphisms of gene XGP and MDR1 and the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy. Practical J Cancer 2007, 22:252-256.
43. Sterne J.A., Gavaghan D., Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000, 53:1119-1129.
44. Lau J., Ioannidis J.P., Terrin N., et al. The case of the misleading funnel plot. BMJ 2006, 333:597-600.
45. Lord R.V., Brabender J., Gandara D., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8:2286-2291.
46. Lenz H.J. The use and development of germline polymorphisms in clinical oncology. J Clin Oncol 2004, 22:2519-2521.
47. Ruzzo A., Graziano F., Kawakami K., et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 2006, 1883-1891.